China's NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products
Policy / Regulatory

China’s NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products

China's National Medical Products Administration (NMPA) released the draft Regulations on the Administration of Radiopharmaceuticals and opened a public comment period through October 20. The draft establishes a dedicated regulatory…

BioMarin's Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World's Largest Rare Bone Disease Market
CompanyDrug

BioMarin’s Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World’s Largest Rare Bone Disease Market

Merck's KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China's Only Approved PD‑1 Perioperative Breast Cancer Therapy
CompanyDrug

Merck’s KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China’s Only Approved PD‑1 Perioperative Breast Cancer Therapy

Novo Nordisk's Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China's Broadest‑Label Long‑Acting Growth Hormone
CompanyDrug

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Novo Nordisk's Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
CompanyDrug

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

NMPA Approves Expanded Indication for Merck's Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China
CompanyDrug

NMPA Approves Expanded Indication for Merck’s Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China

CSPC Initiates Phase Ib Trial of JMT206 – First‑in‑Human Dual ActR‑IIA/IIB Monoclonal Antibody Targeting Weight Management with Muscle Preservation
CompanyDrug

CSPC Initiates Phase Ib Trial of JMT206 – First‑in‑Human Dual ActR‑IIA/IIB Monoclonal Antibody Targeting Weight Management with Muscle Preservation

NMPA Approves Lilly's Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China
CompanyDrug

NMPA Approves Lilly’s Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China

FDA Approves Eli Lilly's Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata
CompanyDrug

FDA Approves Eli Lilly’s Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata

FDA Approves Eli Lilly's Onswik – Once‑Weekly Basal Insulin for Adults With Type 2 Diabetes
CompanyDrug

FDA Approves Eli Lilly’s Onswik – Once‑Weekly Basal Insulin for Adults With Type 2 Diabetes

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value

Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) announced an exclusive licensing agreement with Somnivera, Inc., a U.S. biotechnology company, for an investigational clinical‑stage drug candidate targeting sleep disorders. Under the terms, Nhwa grants Somnivera the exclusive rights to develop, manufacture,…

HitGen Co‑Invests in Connexus Therapeutics' Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing

HitGen Co‑Invests in Connexus Therapeutics’ Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing

MindRank Signs Exclusive Greater China Commercialization Deal With Sunshine Mandi for MDR‑001 – AI‑Designed Oral GLP‑1 Candidate in Phase III for Obesity, Worth Up to RMB 1.75 Billion
CompanyDeals

MindRank Signs Exclusive Greater China Commercialization Deal With Sunshine Mandi for MDR‑001 – AI‑Designed Oral GLP‑1 Candidate in Phase III for Obesity, Worth Up to RMB 1.75 Billion

Sino Biopharmaceutical's CTTQ Partners With STADA on Pembrolizumab Biosimilar TQB3570 – Exclusive European License With Options Across Oncology and Immunology
CompanyDeals

Sino Biopharmaceutical’s CTTQ Partners With STADA on Pembrolizumab Biosimilar TQB3570 – Exclusive European License With Options Across Oncology and Immunology

Sinovac and Egypt's GENNVAX Launch sIPV Technical Cooperation Project in Beijing – Sabin Inactivated Polio Vaccine Localization Deal Enters Implementation Phase
CompanyDeals

Sinovac and Egypt’s GENNVAX Launch sIPV Technical Cooperation Project in Beijing – Sabin Inactivated Polio Vaccine Localization Deal Enters Implementation Phase

Merck Licenses SciBrunch's Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal
CompanyDeals

Merck Licenses SciBrunch’s Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal

AstraZeneca to Invest USD 2 Billion in Summit Therapeutics – Clinical Collaboration Anchored on Ivonescimab and Claudin 18.2 ADC Sone‑Ve
CompanyDeals

AstraZeneca to Invest USD 2 Billion in Summit Therapeutics – Clinical Collaboration Anchored on Ivonescimab and Claudin 18.2 ADC Sone‑Ve

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Novo Nordisk Licenses Hengrui's HRS‑1596 in Up to USD 2.6 Billion Global Deal – Once‑Weekly Oral Candidate for Obesity and Type 2 Diabetes
CompanyDeals

Novo Nordisk Licenses Hengrui’s HRS‑1596 in Up to USD 2.6 Billion Global Deal – Once‑Weekly Oral Candidate for Obesity and Type 2 Diabetes

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced a licensing agreement with Novo Nordisk A/S (NYSE: NVO) for HRS‑1596, an oral candidate with once‑weekly administration potential targeting obesity,…

Novo Nordisk Licenses Nanexa's PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes
CompanyDeals

Novo Nordisk Licenses Nanexa’s PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes

Atavistik Bio Strikes CVRM Collaboration with Roche – USD 70 Million Upfront, up to USD 1.9 Billion in Milestones for Allosteric Small‑Molecule Discovery
CompanyDeals

Atavistik Bio Strikes CVRM Collaboration with Roche – USD 70 Million Upfront, up to USD 1.9 Billion in Milestones for Allosteric Small‑Molecule Discovery

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

Boehringer Ingelheim and WHO Foundation Launch Three‑Year, USD 5 Million Collaboration to Tackle Obesity in Resource‑Limited Settings
CompanyDeals

Boehringer Ingelheim and WHO Foundation Launch Three‑Year, USD 5 Million Collaboration to Tackle Obesity in Resource‑Limited Settings

- Advertisement -
Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom
CompanyDeals

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027
CompanyDeals

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status
CompanyDeals

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter "Care Program – Extension" While GH56 Advances Pediatric Development
Policy / Regulatory

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter “Care Program – Extension” While GH56 Advances Pediatric Development

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) included InnoCare's ICP‑B794 and Hiteck Biological's Aponermin in the "Care Program – Extension" pilot project, while Genhouse…

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
Policy / Regulatory

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented
Policy / Regulatory

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening
Policy / Regulatory

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

More News

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure
CompanyDrug

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis
CompanyDrug

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis

European Commission Revokes Hansoh's Aumolertinib Marketing Authorization – EU Approval Reversed Seven Months After Grant in TAGRISSO Data‑Protection Dispute
CompanyDrug

European Commission Revokes Hansoh’s Aumolertinib Marketing Authorization – EU Approval Reversed Seven Months After Grant in TAGRISSO Data‑Protection Dispute

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China
CompanyDrug

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers
CompanyDrug

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Haisco's HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation
CompanyDrug

Haisco’s HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation

Leads Biolabs' LBL-024 Granted Orphan Drug Designation by Japan's MHLW – Anti‑PD‑L1/4‑1BB Bispecific Antibody Advances in Extrapulmonary Neuroendocrine Carcinoma
CompanyDrug

Leads Biolabs’ LBL-024 Granted Orphan Drug Designation by Japan’s MHLW – Anti‑PD‑L1/4‑1BB Bispecific Antibody Advances in Extrapulmonary Neuroendocrine Carcinoma

Show More